Physician profile
Jackson Okoya
NPI 1174615165
$752.51
in general payments reported to CMS, 2019-2025
16 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.69 · 2020: $98.35 · 2021: $92.48 · 2022: $169 · 2023: $52.44 · 2024: $162 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $129.71 | 2022 | |
| Paratek Pharmaceuticals, INC. | $114.36 | 2024-2025 | Nuzyra |
| Novo Nordisk INC | $103.89 | 2021-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $90.54 | 2019-2020 | |
| Abbvie INC. | $60.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $47.17 | 2023-2024 | |
| Lilly USA, LLC | $31.25 | 2019-2023 | Mounjaro |
| Indivior INC. | $27.72 | 2020 | |
| Glaxosmithkline, LLC. | $25.91 | 2022 | |
| Hologic Sales and Service, LLC | $22.24 | 2024 | Aptima |
| Amgen INC. | $18.33 | 2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $17.42 | 2024 | |
| Gilead Sciences, INC. | $16.88 | 2025 | |
| Xeris Pharmaceuticals, INC. | $16.71 | 2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $16.65 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Okoya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.